



(12) Translation of
European patent specification

(11) NO/EP 3541390 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 487/04 (2006.01)

A61P 11/12 (2006.01)

A61K 31/519 (2006.01)

A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.09.09
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.05.01
(86)	European Application Nr.	17872726.9
(86)	European Filing Date	2017.11.17
(87)	The European Application's Publication Date	2019.09.25
(30)	Priority	2016.11.18, US, 201662423919 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Cystic Fibrosis Foundation, 4550 Montgomery Avenue, Suite 1100 N, Bethesda, MD 20814, USA
(72)	Inventor	STROHBACH, Joseph, Walter, 114 Crockett Creek Drive, Wentzville, MO 63385, USA LIMBURG, David, Christopher, 227 Forsyth Road, Salem, CT 06420, USA MATHIAS, John, Paul, 1338 Main Street, Concord, MA 01742, USA THORARENSEN, Atli, 240 Boxboro Road, Stow, MA 01775, USA DENNY, Rajiah, Aldrin, 40 Harold Street, Sharon, MA 02067, USA ZAPF, Christoph, Wolfgang, 301 Executive Park Boulevard 140, San Francisco, CA 94134, USA ELBAUM, Daniel, 25 Sherrin Road, Newman, MA 02462, USA GAVRIN, Lori, Krim, 306 Clairmont Road, Villanova, PA 19085, USA EFREMOV, Ivan, Viktorovich, 83 Payson Road, Chestnut, MA 02467, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **PYRROLOPYRIMIDINES AS CFTR POTENTIATORS**

(56) References

Cited:

WO-A2-2005/074603, US-A1- 2013 344 061, WO-A1-2014/060431, WO-A2-2009/062118,
US-A1- 2007 203 143, WO-A1-2007/104944, WO-A2-2004/100868, WO-A2-2007/114926,
WO-A1-2015/091532, US-A1- 2007 293 516,
SMART, JANET: "Proteostasis Therapeutics Presents Preclinical Data for Its CFTR Amplifier
Program at the 29th Annual North American Cystic Fibrosis Conference", MARKETWIRED, 8
October 2015 (2015-10-08), pages 1 - 2, XP009515115, Retrieved from the Internet
<URL:https://web.archive.org/web/20180708090548/http://m.marketwired.com/press-
release/proteostasis-therapeutics-inc-presents-preclinical-data-its-cftr-amplifier-program-29th-
2062260.htm> [retrieved on 20180112]
GRAZIANO: "Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in
Cystic Fibrosis", 15 January 2016 (2016-01-15), pages 1 - 4, XP055603533, Retrieved from the
Internet <URL:https://www.globenewswire.com/news-release/2016/01/15/802351/0/en/Nivalis-
Therapeutics-Announces-FDA-Orphan-Drug-Designation-for-N91115-in-Cystic-Fibrosis.html>

KIM ET AL.: "The Protein Kinase 2 Inhibitor CX-4945 Induces Autophagy in Human Cancer Cell Lines", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 35, 2014, pages 2985 - 2989, XP055486635

SCHWEITZER: "ProQR Announces Enrollment Has Started in Global Phase 1 b Study of QR-010 in Cystic Fibrosis Patients", MACDOUGALL BIOMEDICAL COMMUNICATIONS, 26 June 2015 (2015-06-26), pages 1 - 2, XP055487109, [retrieved on 20180112]

SPYRYX: "Spyryx Biosciences to Present Safety, Stability & Effectiveness Data for SPX-101 at the North American Cystic Fibrosis Conference", SPYRYX BIOSCIENCES, 25 October 2016 (2016-10-25), Orlando, FL, pages 1 - 2, XP055487036, Retrieved from the Internet <URL:<https://www.prnewswire.com/news-releases/spyryx-biosciences-to-present-safety-stability-effectiveness-data-for-spx-101-at-the-north-american-cystic-fibrosis-conference-october-27-29-2016-orlando-fl-300350083.html>> [retrieved on 20180112]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

3541390

1

Patentkrav

1. 4-amino-7-[[1-(2-fluorfenyl)-1H-pyrazol-4-yl]metyl]-5-[2-(trifluormetyl)pyrimidin-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-karbonitril eller et farmasøytisk aksepterbart salt
5 derav.
2. 4-amino-7-[[1-(2-fluorfenyl)-1H-pyrazol-4-yl]metyl]-5-[2-(trifluormetyl)pyrimidin-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-6-karbonitril.
- 10 3. 7-[(1S)-1-[1-(2,4-difluorfenyl)-1H-1,2,3-triazol-4-yl]propyl]-5-[2-(trifluormetyl)pyrimidin-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amin eller et farmasøytisk aksepterbart salt derav.
- 15 4. 7-[(1S)-1-[1-(2,4-difluorfenyl)-1H-1,2,3-triazol-4-yl]propyl]-5-[2-(trifluormetyl)pyrimidin-5-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amin.